NCT07216209 The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
| NCT ID | NCT07216209 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arizona |
| Condition | Lung Cancer - Non Small Cell |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2026-01-13 |
| Primary Completion | 2030-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 48 participants in total. It began in 2026-01-13 with a primary completion date of 2030-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is increased interest and knowledge about the lung cancer tumor microenvironment (TME). Investigators hypothesize that patients with better baseline physiologic health will have better post-operative outcomes and that strenuous exercise will alter the TME and genetic make-up of the tumor, improving the tumor immune response. Investigators aim to identify the peri-operative and clinical outcomes that differ based on pre-operative VO2max, HRV and resting heart rate following resection of early-stage lung cancer. The physiologic states that are individual and measurable with wearable devices include but are not limited to VO2max, heart rate variability (HRV), and average resting heart rate. Investgators hypothesize that a patient's pre-operative physiologic function with higher VO2max, HRV and lower resting heart rate will be associated with improved peri-operative and post-operative outcomes. Second, investigators will compare alterations in TME based on targeted pre-operative exercise (60-80% of their VO2 max for 75min/week x2 weeks) compared to normal activity adults following resection of early-stage lung cancer. Investigators hypothesize that strenuous exercise in the pre-operative period will impact the TME by increasing levels of cytokines.
Eligibility Criteria
Inclusion Criteria: * lung cancer * low risk for submaximal exercise testing in accordance with the risk stratification guidelines published by the American Heart Association and the American College of Sports Medicine (AHA/ACSM criteria). Exclusion Criteria: * younger than 18 years of age * select a condition on the ACSM-AHA pre-exercise screening questionnaire indicating that physician approval is required prior to exercise * body mass index of \>30 kg/m2 * waist girth of \>102cm for men and \>88cm for women * have chronic/debilitating arthritis * have been bedridden in the past three months * have common illness (i.e. colds) within the past 6-weeks * HIV * hepatitis * history of stroke * major affective disorder * autoimmune disease * pregnancy or are breast-feeding * history of severe anaphylactic reaction to an allergen * present with more than one of the following CVD risk factors: family history of myocardial infarction, coronary revascularization, or sudden death before 55 years of age in father or other male first-degree relative or before 65 years of age in mother or other female first-degree relative
Contact & Investigator
Stephanie Worrell, MD
PRINCIPAL INVESTIGATOR
University of Arizona
Frequently Asked Questions
Who can join the NCT07216209 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer - Non Small Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07216209 currently recruiting?
Yes, NCT07216209 is actively recruiting participants. Contact the research team at sworrell@arizona.edu for enrollment information.
Where is the NCT07216209 trial being conducted?
This trial is being conducted at Tucson, United States.
Who is sponsoring the NCT07216209 clinical trial?
NCT07216209 is sponsored by University of Arizona. The principal investigator is Stephanie Worrell, MD at University of Arizona. The trial plans to enroll 48 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.